Scarica l'app Stockscreener
2.49
1.97%
-0.05
Precedente Chiudi:
$2.54
Aprire:
$2.7
Volume 24 ore:
229.44K
Relative Volume:
0.45
Capitalizzazione di mercato:
$28.02M
Reddito:
-
Utile/perdita netta:
$-17.12M
Rapporto P/E:
-1.5861
EPS:
-1.5699
Flusso di cassa netto:
$-15.68M
1 W Prestazione:
+26.40%
1M Prestazione:
+6.87%
6M Prestazione:
-37.28%
1 anno Prestazione:
-27.19%
Intervallo 1D:
$2.32
$2.7353
Intervallo di 1 settimana:
$1.8501
$2.82
Portata 52W:
$1.11
$5.7441
Lantern Pharma Inc Stock (LTRN) Company Profile
Nome
Lantern Pharma Inc
Settore
Industria
Telefono
972-277-1136
Indirizzo
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
2.49 | 28.59M | 0 | -17.12M | -15.68M | -1.5699 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 110.81B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 78.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 42.71B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.60B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-07 | Iniziato | H.C. Wainwright | Buy |
Lantern Pharma Inc Borsa (LTRN) Ultime notizie
Funds report 834,752 Lantern Pharma (LTRN) shares in ownership update - Stock Titan
Lantern Pharma (LTRN) Launches AI Platform for Cancer Research - GuruFocus
Lantern Pharma launches AI platform for rare cancer research By Investing.com - Investing.com Australia
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Can - PharmiWeb.com
Lantern Pharma launches AI platform for rare cancer research - Investing.com
Lantern Pharma Inc. Launches withZeta.ai, the Worlds First Multi Agentic AU Co Scientist for Rare Cancer Drug Discovery and Development - marketscreener.com
Lantern Pharma outlines $15B–$20B market potential as AI-driven pipeline advances and funding needs intensify - MSN
Lantern Pharma Showcases withZeta.ai Platform for Rare Cancers - TipRanks
Lantern Pharma showcases withZeta.ai platform, outlines commercial architecture and near-term revenue strategy - TradingView — Track All Markets
Lantern Pharma (NASDAQ: LTRN) showcases withZeta.ai rare cancer AI - Stock Titan
LTRN Technical Analysis & Stock Price Forecast - Intellectia AI
Lantern Pharma (NASDAQ: LTRN) insider holds 570,000 shares, 5.1% stake - Stock Titan
Why is Lantern Pharma stock soaring Monday? - MSN
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... By GuruFocus - Investing.com Canada
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Stra - GuruFocus
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Lantern Pharma (LTRN) to Showcase AI Innovation in Rare Cancer R - GuruFocus
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026 - Yahoo Finance
Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows - Foster's Daily Democrat
Fed Meeting: Whats the outlook for Lantern Pharma Incs sectorWeekly Market Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Progress Index
LTRN PE Ratio & Valuation, Is LTRN Overvalued - Intellectia AI
LTRN stock gains 18% pre-market: FDA greenlights first pediatric cancer trial for AI-driven drug - MSN
Lantern Pharma’s Dramatic Slide Reflects Key Strategic Uncertainties - timothysykes.com
Lantern Pharma Reports 2025 Financial Results - National Today
Lantern Pharma Inc. Announces Proposed Public Offering of Common Stock - Issuewire
Lantern Pharma Q4 2025 Earnings Call Transcript - MarketBeat
Lantern Pharma Q4 2025 slides: EPS beats as cash runway tightens - Investing.com Australia
Lantern Pharma Inc reports results for the quarter ended September 30Earnings Summary - TradingView — Track All Markets
Lantern Pharma Announces Termination of Proposed Public Offering - Issuewire
Lantern Pharma Q4 2025 slides: EPS beats as cash runway tightens By Investing.com - Investing.com South Africa
Lantern Pharma Inc. announces plan for best-efforts public offering of common stock. - bitget.com
Lantern Pharma Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:LTRN) 2026-03-30 - Seeking Alpha
Lantern Pharma (LTRN) Achieves Key Milestones in Oncology Develo - GuruFocus
Lantern Pharma Reports 2025 Results and Pipeline Progress - TipRanks
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - 01net
Lantern Pharma (LTRN) Dismisses False CEO Resignation Rumor - GuruFocus
Lantern Pharma (NASDAQ: LTRN) outlines AI-driven cancer pipeline and going concern risk - Stock Titan
Lantern Pharma (NASDAQ: LTRN) seeks equity via best‑efforts placement with warrants - Stock Titan
Earnings call transcript: Lantern Pharma Q4 2025 sees EPS improvement, stock jumps By Investing.com - Investing.com South Africa
Earnings call transcript: Lantern Pharma Q4 2025 sees EPS improvement, stock jumps - Investing.com Australia
Lantern Pharma (NASDAQ: LTRN) trims 2025 loss as cash runway shrinks into 2026 - Stock Titan
Q4 2025 Lantern Pharma Inc Earnings Call Transcript - GuruFocus
Lantern Pharma : Fourth Quarter 2025 Financial Results Conference Call - marketscreener.com
Lantern Pharma : Fourth Quarter 2025 Presentation - marketscreener.com
Dallas company secures FDA approval for pediatric cancer drug trial - The Business Journals
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report - marketscreener.com
Lantern Pharma (LTRN) price target increased by 25.00% to 25.50 - MSN
Lantern Pharma Shares Rise; What's The Buzz? - RTTNews
Lantern Pharma Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aug Volume: What are Lantern Pharma Incs recent SEC filings showingQuarterly Performance Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
Lantern Pharma Inc Azioni (LTRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lantern Pharma Inc Azioni (LTRN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
| Fletcher Aaron G.L. | 10% Owner |
May 29 '25 |
Sale |
3.03 |
20,200 |
61,206 |
54,792 |
| Fletcher Aaron G.L. | 10% Owner |
May 28 '25 |
Sale |
2.87 |
15,000 |
43,050 |
55,753 |
2.19%
0.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):